Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 30,200 shares, a drop of 16.8% from the February 28th total of 36,300 shares. Currently, 1.6% of the company’s stock are sold short. Based on an average daily volume of 64,800 shares, the days-to-cover ratio is currently 0.5 days.

Hedge Funds Weigh In On Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Virtu Financial LLC purchased a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned approximately 1.11% of Tharimmune as of its most recent filing with the Securities and Exchange Commission (SEC). 1.16% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on THAR. RODMAN&RENSHAW raised shares of Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th. Rodman & Renshaw initiated coverage on shares of Tharimmune in a report on Friday, December 6th. They issued a “buy” rating and a $17.00 price target for the company.

Tharimmune Stock Performance

Shares of THAR opened at $1.35 on Tuesday. The firm has a market cap of $2.62 million, a PE ratio of -0.14 and a beta of 1.28. The firm’s 50 day moving average price is $1.71 and its 200 day moving average price is $2.08. Tharimmune has a twelve month low of $1.20 and a twelve month high of $7.46.

Tharimmune (NASDAQ:THAR) last announced its earnings results on Tuesday, March 25th. The company reported ($2.02) earnings per share (EPS) for the quarter.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).